The use of Antibody drug conjugates as therapeutic agents is hugely attractive, offering the potential to effective target delivery of a drug to specific site and thus improving efficacy while also reducing toxicity through off target effects. ADCs comprise of 3 components, a drug, a linker and a monoclonal antibody. There are often viewed as a biologic and a small molecule and thus subject to a guidance / regulatory framework covering both. But is this correct?
This Online course will examine the challenges posed in effective and appropriate management of impurities. It will examine each type of Impurity, process and product related, and crucially, the risk posed by conjugated and non-conjugated impurities. In an area lacking an appropriate guidance framework it will examine the latest thinking and how this could shape the future approach taken to effective impurity management
The course will be held over two Live Sessions as follows in UK time:
Wednesday, November 19 | 1.30pm – 5.30pm GMT
Thursday, November 20 | 1.30pm – 5.30pm GMT
Andy also runs the fantastic Practical Management of Impurities and Development of Effective and Comprehensive Control Strategies.
This Online course will examine the challenges posed in effective and appropriate management of impurities. It will examine each type of Impurity, process and product related, and crucially, the risk posed by conjugated and non-conjugated impurities. In an area lacking an appropriate guidance framework it will examine the latest thinking and how this could shape the future approach taken to effective impurity management
The course will be held over two Live Sessions as follows in UK time:
Wednesday, November 19 | 1.30pm – 5.30pm GMT
Thursday, November 20 | 1.30pm – 5.30pm GMT
Andy also runs the fantastic Practical Management of Impurities and Development of Effective and Comprehensive Control Strategies.
